NewAmsterdam Pharma (NASDAQ:NAMS) CAO Sells $3,055,500.00 in Stock

NewAmsterdam Pharma (NASDAQ:NAMS) CAO Louise Frederika Kooij sold 150,000 shares of the company’s stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $20.37, for a total value of $3,055,500.00. Following the sale, the chief accounting officer now owns 15,000 shares in the company, valued at approximately $305,550. This represents a 90.91 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

NewAmsterdam Pharma Trading Up 7.1 %

NAMS stock opened at $23.02 on Thursday. The company’s 50 day moving average is $22.30 and its 200 day moving average is $20.41. The stock has a market cap of $2.13 billion, a price-to-earnings ratio of -8.85 and a beta of -0.06. NewAmsterdam Pharma has a 1-year low of $15.19 and a 1-year high of $27.29.

NewAmsterdam Pharma (NASDAQ:NAMS) last posted its quarterly earnings data on Wednesday, February 26th. The company reported ($0.95) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.47). The company had revenue of $12.77 million for the quarter, compared to the consensus estimate of $3.30 million. As a group, sell-side analysts forecast that NewAmsterdam Pharma will post -1.75 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently weighed in on NAMS. HC Wainwright reiterated a “buy” rating and set a $48.00 price target on shares of NewAmsterdam Pharma in a research report on Tuesday, January 14th. Needham & Company LLC decreased their price target on NewAmsterdam Pharma from $46.00 to $42.00 and set a “buy” rating on the stock in a research report on Thursday, February 27th. Scotiabank upped their price target on NewAmsterdam Pharma from $47.00 to $52.00 and gave the company a “sector outperform” rating in a research report on Thursday, February 27th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $40.00 price objective on shares of NewAmsterdam Pharma in a research report on Friday, January 24th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, NewAmsterdam Pharma currently has an average rating of “Buy” and an average price target of $43.80.

Institutional Trading of NewAmsterdam Pharma

Several hedge funds and other institutional investors have recently bought and sold shares of the company. GF Fund Management CO. LTD. purchased a new stake in NewAmsterdam Pharma in the fourth quarter worth approximately $50,000. Frazier Life Sciences Management L.P. boosted its stake in NewAmsterdam Pharma by 23.8% in the fourth quarter. Frazier Life Sciences Management L.P. now owns 15,916,418 shares of the company’s stock worth $409,052,000 after buying an additional 3,061,224 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in NewAmsterdam Pharma by 6.0% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 253,571 shares of the company’s stock worth $6,517,000 after buying an additional 14,288 shares in the last quarter. Voloridge Investment Management LLC purchased a new stake in NewAmsterdam Pharma in the fourth quarter worth approximately $721,000. Finally, Woodline Partners LP boosted its stake in NewAmsterdam Pharma by 108.7% in the fourth quarter. Woodline Partners LP now owns 2,430,782 shares of the company’s stock worth $62,471,000 after buying an additional 1,266,105 shares in the last quarter. Hedge funds and other institutional investors own 89.89% of the company’s stock.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.